相关临床试验
13
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
15.4%
已完成
1
7.7%
招募中
10
76.9%
暂无批准数据
- Two new studies from Bellvitge University Hospital and IDIBELL identify molecular signatures and digital tools that may enable more personalized monitoring of amyotrophic lateral sclerosis (ALS) progression. - A Brain Pathology study found that aggressive ALS forms have distinct cerebrospinal fluid protein signatures, identifying CXCL7 as a potential complementary biomarker to neurofilaments. - An international study in Annals of Clinical and Translational Neurology demonstrated that home-based digital tools, particularly speech assessments, reliably reflect functional status in ALS patients. - Researchers aim to integrate biological biomarkers, genetic data, and digital technologies to build predictive models that stratify patients and accelerate development of subgroup-targeted treatments.
- New data from the 2026 International Liver Transplantation Society Congress demonstrates that Bridge to Life's VitaSmart Hypothermic Oxygenated Perfusion (HOPE) technology improves utilization of marginal donor livers including steatotic and older organs. - Studies show HOPE enables higher utilization rates of previously discarded liver grafts from controlled donation after circulatory death, increasing from 1% to 5.8% when complications arise during normothermic regional perfusion. - Research confirms that prolonged HOPE up to 24 hours maintains mitochondrial function and structural integrity comparable to standard short-duration perfusion, providing logistical advantages for transplant scheduling. - Flavin mononucleotide (FMN) emerges as a potential biomarker for real-time organ viability assessment, with donor serum FMN levels correlating with graft quality and transplant outcomes.
